PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis-Reference-Cited by-同舟云学术

PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis

Published:2017-07-03 Issue:7 Volume:12 Page:e0180346
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yvorel Violaine,Patoir Arnaud,Casteillo François,Tissot Claire,Fournel Pierre,Stachowicz Marie-Laure,Karpathiou Georgia,Tiffet Olivier,Péoc’h Michel,Forest Fabien^ORCID

Funder

Ligue Contre le Cancer

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference20 articles.

1. Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies;F Forest;Hum Pathol,2016

2. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer;M Reck;N Engl J Med,2016

3. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages;T Vieira;Lung Cancer,2016

4. WHO classification of tumours of lung, pleura, thymus and heart;WD Travis,2015

5. PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of Tissue Micro Arrays;G Botti;Int J Mol Sci,2016

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tracing Tumor Heterogeneity of Pleomorphic Carcinoma of the Lung;Journal of Thoracic Oncology;2024-09

2. Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study;Frontiers in Immunology;2024-07-15

3. Pulmonary sarcomatoid carcinoma: A rare case report, diagnostic dilemma and review of literature;Medicine;2024-07-05

4. Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example;Molecular Biomedicine;2024-04-15

5. Analysis of PD-1/PD-L1 variations in lung cancer and association with immunotherapeutic efficacy and prognosis: A nonrandomized controlled trial;Clinics;2024-01